4-chloro-2-(4-chloro-2,6-dimethylphenoxy)-6-methylnicotinic acid chloride | 1013933-40-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-chloro-2-(4-chloro-2,6-dimethylphenoxy)-6-methylnicotinic acid chloride
• 英文别名: 4-Chloro-2-(4-chloro-2,6-dimethylphenoxy)-6-methylpyridine-3-carbonyl chloride
• CAS: 1013933-40-8
• 化学式: C₁₅H₁₂Cl₃NO₂
• 分子量: 344.625
• InChiKey: KBVXOLJNNAOJLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-chloro-2-(4-chloro-2,6-dimethylphenoxy)-6-methylnicotinic acid chloride 、 甲胺 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 4-chloro-2-(4-chloro-2,6-dimethylphenoxy)-N,6-dimethylpyridine-3-carboxamide
  参考文献：
  名称：

  2-Aryloxy-4-alkylaminopyridines: Discovery of Novel Corticotropin-Releasing Factor 1 Antagonists

  摘要：

  An orally active clinical candidate of corticotropin-releasing factor 1 (CRF(1)) antagonist 1 showed a significant positive food effect in dog and human after oral administration. Efforts to address the food effect issue led us to explore and discover compounds in series 2 as orally active CRF(1) receptor antagonists, in which some compounds showed improved physicochemical properties while retaining desired pharmacological properties. Compound 3a (CP-376395) was selected for further development, due not only to its reduced food effects but also its greater efficacy in CNS models. Compound 3a was advanced to the clinic. The synthesis of representative potential candidates and their in vitro, ex vivo, and in vivo data are described.

  DOI：

  10.1021/jm070579c
• 作为产物：
  描述：

  4-Chloro-2-(4-chloro-2,6-dimethylphenoxy)-6-methylpyridine-3-carboxylic acid 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 4-chloro-2-(4-chloro-2,6-dimethylphenoxy)-6-methylnicotinic acid chloride
  参考文献：
  名称：

  2-Aryloxy-4-alkylaminopyridines: Discovery of Novel Corticotropin-Releasing Factor 1 Antagonists

  摘要：

  An orally active clinical candidate of corticotropin-releasing factor 1 (CRF(1)) antagonist 1 showed a significant positive food effect in dog and human after oral administration. Efforts to address the food effect issue led us to explore and discover compounds in series 2 as orally active CRF(1) receptor antagonists, in which some compounds showed improved physicochemical properties while retaining desired pharmacological properties. Compound 3a (CP-376395) was selected for further development, due not only to its reduced food effects but also its greater efficacy in CNS models. Compound 3a was advanced to the clinic. The synthesis of representative potential candidates and their in vitro, ex vivo, and in vivo data are described.

  DOI：

  10.1021/jm070579c

文献信息

• 2-Aryloxy-4-alkylaminopyridines: Discovery of Novel Corticotropin-Releasing Factor 1 Antagonists
  作者：Yuhpyng L. Chen、R. Scott Obach、John Braselton、Michael L. Corman、James Forman、Jody Freeman、Randall J. Gallaschun、Robert Mansbach、Anne W. Schmidt、Jeffrey S. Sprouse、F. David Tingley, III、Elizabeth Winston、David W. Schulz

  DOI：10.1021/jm070579c

  日期：2008.3.13

  An orally active clinical candidate of corticotropin-releasing factor 1 (CRF(1)) antagonist 1 showed a significant positive food effect in dog and human after oral administration. Efforts to address the food effect issue led us to explore and discover compounds in series 2 as orally active CRF(1) receptor antagonists, in which some compounds showed improved physicochemical properties while retaining desired pharmacological properties. Compound 3a (CP-376395) was selected for further development, due not only to its reduced food effects but also its greater efficacy in CNS models. Compound 3a was advanced to the clinic. The synthesis of representative potential candidates and their in vitro, ex vivo, and in vivo data are described.